Holen Sie sich die Stockscreener-App
276.27
1.78%
4.82
Handel nachbörslich:
276.28
0.010
+0.00%
Schlusskurs vom Vortag:
$271.45
Offen:
$273
24-Stunden-Volumen:
1.86M
Relative Volume:
1.21
Marktkapitalisierung:
$39.57B
Einnahmen:
$2.50B
Nettoeinkommen (Verlust:
$-226.32M
KGV:
-168.33
EPS:
-1.6412
Netto-Cashflow:
$71.51M
1W Leistung:
+6.27%
1M Leistung:
+26.26%
6M Leistung:
+20.59%
1J Leistung:
+71.90%
1-Tages-Spanne:
$266.33
$279.42
1-Wochen-Bereich:
$257.07
$279.42
52-Wochen-Spanne:
$131.81
$279.42
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
276.27 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
513.33 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
193.72 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
537.58 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
133.39 | 37.52B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | William Blair | Outperform |
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Form 144 NATERA For: 1 July By Investing.com - Investing.com Canada
Insider 10b5-1 sales reported for NTRA (NTRA) including 33,600 shares - Stock Titan
Director Solomon Moshkevich reports share sales (NTRA) - Stock Titan
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer - Yahoo Finance UK
Form 4 Natera Inc For: 30 June By Investing.com - Investing.com Australia
Roelof Botha of Natera (NTRA) granted RSUs and reports over 1.08M shares - Stock Titan
Natera (NASDAQ: NTRA) director receives RSU grants as board compensation - Stock Titan
Enterprise value to EBIT forward of Natera, Inc. – NASDAQ:NTRA - TradingView
Enterprise value to revenue forward of Natera, Inc. – NASDAQ:NTRA - TradingView
Natera Stock 5-Day Winning Spree: Stock Climbs 19% - Trefis
Natera Stock Surges 19%, With A 5-Day Winning Spree - Trefis
3 Stocks Estimated To Be Trading At A Discount Of Up To 48.9% - simplywall.st
Price to sales forward of Natera, Inc. – NASDAQ:NTRA - TradingView
Natera, Aveta Biomics collaborate on head and neck cancer trial - Clinical Trials Arena
Price to earnings forward of Natera, Inc. – NASDAQ:NTRA - TradingView
NTRA & CytoDyn partner to advance ctDNA-guided development in mCRC - MSN
META_TITLE_QUOTE - Yahoo Finance
Natera, Aveta Biomics Ink Partnership to Support Phase III Trial in Head and Neck Cancer - Contract Pharma
Medical Services Name Tests For Colon Cancer. Natera Stock Hits A High. - Investor's Business Daily
NTRA Maintained by Guggenheim -- Price Target Raised to $290 - GuruFocus
Natera, Aveta partner on late-stage head and neck cancer trial - TradingView
Natera partners with Aveta for phase 3 head and neck cancer trial - Investing.com South Africa
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer - Lelezard
Natera partners with Aveta for phase 3 head and neck cancer trial By Investing.com - Investing.com India
Natera joins Aveta's global Phase 3 head and neck cancer trial - Stock Titan
Price to book forward of Natera, Inc. – NASDAQ:NTRA - TradingView
Supreme Court Declines to Hear CareDx Appeal in Natera False-Advertising CaseHealthcare Earnings Report - dars.gov.et
U.S. Supreme Court Rejects CareDxA’s Appeal in Natera, Inc. (NTRA) False-advertising Dispute - Insider Monkey
Natera climbs after Japanese nod for colorectal cancer test - MSN
Price-Driven Insight from (NTRA) for Rule-Based Strategy - Stock Traders Daily
Form 4 Natera Inc For: 26 June By Investing.com - Investing.com Nigeria
Natera director Herm Rosenman sells $4.13m in common stock - Investing.com UK
Natera(NTRA.US) Officer Sells US$8.46 Million in Common Stock - Moomoo
Insider Sell Alert: Herm Rosenman Sells 16,530 Shares of Natera Inc (NTRA) - GuruFocus
Natera director Herm Rosenman sells $4.13m in common stock By Investing.com - Investing.com Australia
Natera Inc (NTRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Natera legal officer Daniel Rabinowitz sells $8.45m in shares - Investing.com
Natera legal officer Daniel Rabinowitz sells $8.45m in shares By Investing.com - Investing.com South Africa
Natera (NTRA) director’s 10b5-1 sale leaves 4,250 shares - Stock Titan
Natera (NTRA) chief legal officer sells 33,600 shares in pre-set 10b5-1 trades - Stock Titan
Natera(NTRA.US) Director Sells US$4.13 Million in Common Stock - Moomoo
Bernstein resumes Natera stock coverage with outperform rating By Investing.com - Investing.com Australia
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial - simplywall.st
Natera (NTRA) Receives Outperform Rating and $310 Target from Be - GuruFocus
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise - Seeking Alpha
Bernstein resumes Natera stock coverage with outperform rating - Investing.com UK
NTRA Reiterated by Bernstein -- Price Target Announced at $310 - GuruFocus
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling - Kavout | AI
Bernstein Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $310 - Moomoo
What's Driving Natera's Recent Stock Action - Kavout | AI
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):